FGF23 and cancer: Some patients received anti-cancer therapies, including doxorubicin (inhibiting DNA/RNA synthesis) (28), burosumab (a monoclonal antibody targeting FGF-23) (29, 30), or infigratinib (an FGF receptor inhibitor) (31).